Antiepileptic treatment against clustered seizures in benign partial epilepsy in infancy

Akihisa Okumura1, Toru Kato, Fumio Hayakawa

  • 1Department of Pediatrics, Nagoya University Graduate School of Medicine, and Department of Pediatrics, Okazaki City Hospital, Japan. okumura@med.nagoya-u.ac.jp

Brain & Development
|May 30, 2006
PubMed

Insights

Phenobarbital showed higher initial efficacy for clustered seizures in benign partial epilepsy in infancy compared to diazepam/bromazepam. However, neither drug proved sufficient for complete seizure cessation in this acute condition.

Area of Science:

  • Pediatric Neurology
  • Epileptology

Background:

  • Benign partial epilepsy in infancy presents with clustered seizures requiring effective acute treatment.
  • Optimal antiepileptic drug (AED) strategies for acute seizure clusters in this condition remain under investigation.

Purpose of the Study:

  • To determine the optimal antiepileptic treatment for clustered seizures during the acute phase of benign partial epilepsy in infancy.
  • To evaluate the efficacy of different AEDs in managing acute seizure clusters.

Main Methods:

  • Retrospective review of 20 patients with benign partial epilepsy in infancy.
  • Analysis of antiepileptic drug treatment details, including temporal seizure course and drug effectiveness.
  • Drugs were assessed for efficacy based on seizure cessation post-administration.

Main Results:

  • Phenobarbital demonstrated higher initial efficacy (60%) compared to diazepam/bromazepam (14%) as a first-line treatment for clustered seizures.
  • Phenobarbital also showed better efficacy as a third-line agent (56%).
  • Patients treated with phenobarbital as the first two drugs experienced shorter seizure persistence and fewer post-treatment seizures.

Conclusions:

  • The initial efficacy of phenobarbital for clustered seizures in benign partial epilepsy in infancy was superior to diazepam/bromazepam.
  • Current AEDs, including diazepam/bromazepam and phenobarbital, show insufficient efficacy for complete cessation of clustered seizures in this specific epilepsy syndrome during the acute phase.

Related Concept Videos

Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...